MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oiry, C.
Right arrow Articles by Martinez, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oiry, C.
Right arrow Articles by Martinez, J.

0026-895X/97/020292-08$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 52:292-299 (1997).

CholecystokininB Receptor from Human Jurkat Lymphoblastic T Cells Is Involved in Activator Protein-1-Responsive Gene Activation

Catherine Oiry, Didier Gagne, Éric Cottin, Nicole Bernad, Jean-Claude Galleyrand, Gilbert Bergé, Marie-Francoise Lignon, Patrick Eldin, Martine Le Cunff, Jean Léger, Pascal Clerc, Daniel Fourmy, and Jean Martinez

Laboratoire des Amino Acides, Peptides et Protéines (L.A.P.P.) ESA.CNRS 5075, Universités de Montpellier I et II Faculté de Pharmacie, 34060 Montpellier, France (C.O., D.G., E.C., N.B., J.-C.G., G.B., M.-F.L., J.M.), Institut National de la Santé et de la Recherche Médicale U300, Faculté de Pharmacie, 34060 Montpellier, France (P.E., M. le C., J.L.), and Institut National de la Santé et de la Recherche Médicale U151, Centre Hospitalier Universitaire Rangueil, 31054 Toulouse, France (P.C., D.F.)

The aim of this study was to analyze the role of cholecystokinin (CCKB) receptor in human lymphoblastic Jurkat T cells. We investigated the trophic effect resulting from activation of such a receptor by using the reporter gene strategy. For this purpose, we transiently transfected Jurkat T cells with the reporter plasmid p[(TRE)3-tk-Luc] and found that CCK-8 was able to dose-dependently induce luciferase expression related to activator protein-1 (AP-1) activation with a maximal response identical to that obtained with compounds known to activate AP-1 complex (quantitatively, the same level of induction was obtained with 1 nM 12-O-tetradecanoylphorbol-13-acetate, 100 µM diacylglycerol, or 4 nM epidermal growth factor). The involvement of the CCKB receptor in such a stimulation was demonstrated by the inhibiting effect of the selective CCKB receptor antagonist PD-135,158. This effect was confirmed in COS-7 cells transfected with the cDNA of CCKB receptor cloned from Jurkat T cells. To better understand the AP-1-dependent luciferase expression in Jurkat T cells, we tested two specific inhibitors of serine/threonine phosphatases-1 and -2A: okadaic acid and calyculin A. These compounds strongly increased the phorbol-12-myristate-13-acetate response, whereas we have not observed a contribution of phosphatase inhibitors on a CCK-8-induced luciferase activity. To confirm that CCKB receptors are involved in AP-1 response, we investigated the CCK-8 effect on interleukin-2 expression, a natural endogenous gene regulated by several factors, including AP-1. In Jurkat T cells activated by phorbol-12-myristate-13-acetate and phytohemagglutinin, CCK-8 induced IL-2 expression. This induction was abolished by PD-135,158. Our results indicate that CCK-8 exerts a trophic effect in Jurkat T cells through stimulation of CCKB receptors by modulation of expression of AP-1-regulated genes.


Copyright © by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Physiol. Rev.Home page
M. Dufresne, C. Seva, and D. Fourmy
Cholecystokinin and gastrin receptors.
Physiol Rev, July 1, 2006; 86(3): 805 - 847.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Morel, G. Ibarz, C. Oiry, E. Carnazzi, G. Berge, D. Gagne, J.-C. Galleyrand, and J. Martinez
Cross-interactions of Two p38 Mitogen-activated Protein (MAP) Kinase Inhibitors and Two Cholecystokinin (CCK) Receptor Antagonists with the CCK1 Receptor and P38 MAP Kinase
J. Biol. Chem., June 3, 2005; 280(22): 21384 - 21393.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. Pannequin, C. Oiry, C. Morel, J. Kucharczak, I. Camby, R. Kiss, D. Gagne, J.-C. Galleyrand, and J. Martinez
C-Terminal Heptapeptide of Gastrin Inhibits Astrocytomas Motility by Interacting with a New Gastrin Binding Site
J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 274 - 282.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Poosti, L. di Malta, D. Gagne, N. Bernad, J.-C. Galleyrand, C. Escrieut, S. Silvente-Poirot, D. Fourmy, and J. Martinez
The Third Intracellular Loop of the Rat and Mouse Cholecystokinin-A Receptors Is Responsible for Different Patterns of Gene Activation
Mol. Pharmacol., April 13, 2001; 58(6): 1381 - 1388.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics